Priavoid’s pharmaceutical development pipeline with anti-prionic drug candidates is composed of 5 development programs for 5 CNS diseases:
- Alzheimer’s disease
- Parkinson’s disease
- Amyotrophic Lateral Sclerosis
- Huntington’s disease
is the most advanced drug in our pipeline for the causal treatment of Alzheimer’s disease (AD).
Thus, PRI-002 has three unique selling propositions (USPs):
New mechanism of action
Specific elimination of toxic Aβ oligomers
New drug substance class
Oral drug administration
Priavoid developed a completely new therapeutic strategy for the causal treatment of Alzheimer’s disease. The orally available D-peptide PRI-002 permeates the blood-brain barrier effectively, does not interfere with formation or clearance of non-toxic Aß monomers, but specifically eliminates cytotoxic Aß-oligomers.